Researchers at the University of Minnesota, world leaders in the treatment of Epidermolysis Bullosa (EB), have developed a stem cell treatment [utilizing mesenchymal stem cells – MSCs] to treat the disorder. This devastating condition involves problems with connective tissue, making skin blister and tear with the slightest contact; severe cases impact internal organ tissues as well. Affecting 1 in every 20,000 children, the disorder can lead to severe infections and be fatal. The team at the University utilized a treatment involving complete renewal of the immune system through chemotherapy and a bone marrow transplant, followed by the administration of mesenchymal stem cells to regenerate the skin tissue.
The use of mesenchymal stem cells proved to be more successful than other therapies to restore the skin’s durability by producing the vital collagen. “They will graft into the skin, set up shop there. It’s as if these mesenchymal stem cells are coming home,” commented Dr. Jakub, director of the University’s Stem Cell Institute.
As regenerative engineering progresses, we believe the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.